Report Id: SNS/HC/2654 | July 2022 | Region: Global | 135 Pages
Report Scope & Overview:
The Growth Hormone Deficiency Market Size was valued at USD 12.15 billion in 2021 and is expected to reach USD 54.96 billion by 2028, and grow at a CAGR of 4.72% over the forecast period 2022-2028.
During the forecast period, the growth hormone deficiency market is expected to expand substantially. According to the American Academy of Pediatrics, growth hormone deficiency (GDH) affects less than one in 3,000 to one in 10,000 children in the United States. GHD is a medical condition characterised by the anterior pituitary gland's insufficient production of somatropin, a growth hormone necessary for cell development and reproduction. Inadequate growth hormone production causes children to grow slowly and puberty to be delayed. When it comes to growth hormone deficiency, adults and children experience various symptoms. Growth hormone deficit is addressed with daily or weekly growth hormone injections, with therapy showing results in 2-3 months.
Growth hormone deficiency has become a big burden for the healthcare profession, with brain injury being the most common cause. This disorder is characterised by a variety of symptoms, including low energy levels, altered body composition, decreased muscle strength, insulin resistance, osteoporosis, and lipid abnormalities such as elevated LDL cholesterol and others. In a nutshell, the growing GH deficient conditions worldwide are predicted to boost growth hormone market share.
Growth hormone deficiency problems and increased expansion hormone usage to counteract ageing are driving market growth.
The human growth hormone market is being propelled by increased knowledge of the treatment technique and an increase in neuropsychiatric cases.
Synthetic growth hormone side effects such as fluid retention, joint pain, and muscular soreness are major major hindrances to market growth.
The high cost of treatment, as well as changes in medication productivity in pharmaceutical businesses, limit market expansion.
The increased number of FDA approvals is also offering opportunity for important businesses to create novel medications with fewer adverse effects.
Increase in the number of R&D activities
IMPACT OF COVID-19:
Following the COVID-19 epidemic, the focus has switched to increased manufacture of effective and affordable medications, with the pandemic shedding light on healthcare disparities. The necessity for real-world evidence has expanded significantly because to the quicker drug development tempo, with large corporations now choosing for remote monitoring as well as source document verification (SDV), guaranteeing that patients can benefit despite the COVID-19 epidemic. While COVID-19 is receiving attention in the medical community, growth hormone insufficiency remains a priority in many countries. As a result, research is being conducted to determine the significance of growth hormone medications and to expand their use reach. The demand for paediatric growth hormones has also been positive in the post-pandemic era.
Norditropin will be the World's Leading Brand. To name a few, the top human growth hormone brands studied in the MRFR report are genotropin, norditropin, saizen, omnitrope, and humatrope. Norditropin has maintained the top brand in the global market since 2021 and is expected to continue growing at a rapid pace over the evaluation period. Norditropin HGH injections are Novo Nordisk's offering and one of the most popular premixed and prefilled human growth hormone brands.
Growth Hormone will be used extensively in GH deficiency cases.
The principal applications of growth hormones are in idiopathic, growth hormone deficit, small for gestational age, short stature, prader-willi syndrome, turner syndrome, and other conditions.
GH deficiency dominates the global market and will most likely continue to do so during the projection period.
Leading Hospital Pharmacy Distribution Channel
The industry is divided into four distribution channels retail pharmacies, hospital pharmacies, e-commerce websites, and clinics. The highest share has gone to hospital pharmacy, owing to an increase in hospital visits as a result of increasing public awareness of GH insufficiency and treatment options. Furthermore, internet pharmacies are growing popularity in both established regions such as Europe and North America, as well as emerging countries such as India and China.
Eli Lilly and Company, Roche, Ipsen, Ferring B.V., Novo Nordisk A/S, Pfizer, Inc, Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Novartis AG, Merck KGaA.
by End User
Growth Hormone Deficiency
Idiopathic Short Stature
Small for Gestational Age
During the projection period, North America is expected to have the biggest market share. The region's dominance is related to variables such as high healthcare expenditure and increased intake of human growth hormone therapy in order to cure various diseases such as Turner syndrome. Furthermore, the ease of access to artificial growth hormones, an increase in human growth hormone research and development, and the availability of reimbursements are all contributing to regional expansion.
In the growth hormone deficiency market, Europe is expected to have the second-largest market share.
The increased prevalence of growth hormone deficiencies, the increasing preference for growth hormones for the treatment of Idiopathic Short Stature (ISS), and rising government spending for healthcare facilities in the region are all contributing to the region's growth.
Asia-Pacific is predicted to increase at the quickest rate during the projection period. Factors such as an increase in the incidence of growth hormone deficient illnesses, an increase in healthcare expenditure, the infiltration of leading players, a growing population, and an increase in disposable income are expected to fuel Asia-Pacific growth.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 12.15 Billion|
|Market Size by 2028||US$ 54.96 Billion|
|CAGR||CAGR of 4.72% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• by End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Specialty Pharmacy)
• by Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader–Willi Syndrome, Small for Gestational Age, and Others)
• by Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and Others)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Eli Lilly and Company, Roche, Ipsen, Ferring B.V., Novo Nordisk A/S, Pfizer, Inc, Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Novartis AG, Merck KGaA.|
|Key Drivers||• Growth hormone deficiency problems and increased expansion hormone usage to counteract ageing are driving market growth.|
|RESTRAINTS||• Synthetic growth hormone side effects such as fluid retention, joint pain, and muscular soreness are major major hindrances to market growth.|
Frequently Asked Questions (FAQ) :
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8.Growth Hormone Deficiency Market, by End User
8.1 Hospital Pharmacy
8.2 Retail Pharmacy
8.3 Online Pharmacy
8.4 Specialty Pharmacy
9.Growth Hormone Deficiency Market, by Application
9.1 Growth Hormone Deficiency
9.2 Turner Syndrome
9.3 Idiopathic Short Stature
9.4 Prader–Willi Syndrome
9.5 Small for Gestational Age
10.Growth Hormone Deficiency Market, by Brand
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12.1 Eli Lilly and Company
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.4 Ferring B.V.
12.5 Novo Nordisk A/S
12.6 Pfizer, Inc
12.7 Ferring Pharmaceuticals
12.8 Teva Pharmaceutical Industries, Ltd
12.9 Novartis AG
12.10 Merck KGaA
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of the good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.